Drugs / KHN702
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07277933 | Dec 2025 → Feb 2026 overdue | — | Chengdu Kanghong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07044960 | Jun 2025 → Apr 2026 overdue | — | Chengdu Kanghong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KHN702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07277933 ↗ |
| Route | Oral | “KHN702 tablet or matching placebo orally in fasted state” NCT07044960 ↗ |